PT - JOURNAL ARTICLE AU - Matthias M. Schneider AU - Marc Emmenegger AU - Catherine K. Xu AU - Itzel Condado Morales AU - Priscilla Turelli AU - Manuela R. Zimmermann AU - Beat M. Frey AU - Sebastian Fiedler AU - Viola Denninger AU - Georg Meisl AU - Vasilis Kosmoliaptsis AU - Heike Fiegler AU - Didier Trono AU - Tuomas P. J. Knowles AU - Adriano Aguzzi TI - Microfluidic Affinity Profiling reveals a Broad Range of Target Affinities for Anti-SARS-CoV-2 Antibodies in Plasma of Covid Survivors AID - 10.1101/2020.09.20.20196907 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.20.20196907 4099 - http://medrxiv.org/content/early/2020/09/23/2020.09.20.20196907.short 4100 - http://medrxiv.org/content/early/2020/09/23/2020.09.20.20196907.full AB - The clinical outcome of SARS-CoV-2 infections can range from asymptomatic to lethal, and is thought to be crucially shaped by the quality of the immune response which includes antibody titres and affinity for their targets. Using Microfluidic Antibody Affinity Profiling (MAAP), we determined the aggregate affinities and concentrations of anti-SARS-CoV-2 antibodies in plasma samples of 42 seropositive individuals, 23 of whom were confirmed to be SARS-CoV-2-positive by PCR testing. We found that dissociation constants (Kd) of anti-RBD antibodies spanned more than two orders of magnitude from 80 pM to 25 nM, despite having similar antibody concentrations. The tested individuals showed progressively higher antibody concentrations but constant Kd values, suggesting that affinities did not mature over time. 33 sera showed affinities higher than that of the CoV2 spike for its ACE2 receptor. Accordingly, addition of seropositive plasma to pre-formed spike-ACE2 receptor complexes led to their dissociation. Finally, we observed that the RBD of HKU1, OC43, and SARS-CoV coronaviruses, but not unrelated control proteins, were able to compete substantially with the RBD of SARS-CoV-2 in solution. Therefore, the affinity of total plasma immunoglobulins to SARS-CoV-2 is an indicator of the quality of the immune response to SARS-CoV-2, and may help select the most efficacious samples for therapeutic plasmapheresis.Competing Interest StatementTPJK is a member of the board of directors of Fluidic Analytics. AA is a member of the board of directors of Mabylon AG which has funded antibody-related work in the Aguzzi lab in the past. VD, SF, HF are employees of Fluidic Analytics. All other authors declare no competing interests.Funding StatementWe acknowledge financial support from the BBRSC to TPJK, as well as the Frances and Augustus Newman Foundation to TPJK. The ERC PhyProt (agreement no. 337969) to MMS, CKX, MRZ, GM and TPJK. The Centre for Misfolding Diseases, Cambridge to MMS, CKX, GM, and TPJK. St John's College Cambridge to MMS, MRZ and TPJK. CKX and MRZ acknowledge funding from the Herchel Smith Fund. ICM acknowledges funding from the Swiss FCS. Institutional core funding by the University of Zurich and the University Hospital of Zurich to AA, as well as Driver Grant 2017DRI17 of the Swiss Personalized Health Network to AA. Funding by grants of Innovation Fund of the University Hospital Zurich to AA and ME. VK acknowledges funding from NIHR (PDF-2016-09-065).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All experiments and analyses involving samples from human donors were conducted with the approval of the local ethics committee of the Canton Zurich (Kantonale Ethikkommission Kanton Zurich). The study is covered by the following applications to above-mentioned local ethics committee: KEK-ZH-Nr. 2015-0561, BASEC-Nr. 2018-01042, and BASEC-Nr. 2020-01731. We obtained approval for all applications. The experiments and analyses were carried out in accordance with the provisions of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Conference on Harmonisation.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data underlying this study will be made available upon reasonable request. The biobank samples are limited and were exhausted in several instances. Therefore, while we will make efforts to provide microliter amounts of samples to other researchers, their availability is physically limited.